Category: Novel Drug Delivery

Update: Isis Biopolymer raises another $3 million

March 3, 2010 by MassDevice staff

Isis Biopolymer Inc., a company developing a new generation of non-invasive drug delivery patches, has raised $3 million through an equity sale to existing investors.

The Providence, R.I.-based firm has developed the Isis Patch, a compact, wireless, active iontophoretic patch using a design that implements advances in microprocessors, thin film batteries, biopolymers and adhesives.

In a statement sent to MassDevice, CEO Emma Durand said the current round "clearly shows the confidence of the investment community in Isis Biopolymer and our innovative transdermal drug delivery and biosensor technology."

Echo Therapeutics readies Prelude SkinPrep for clinical trials

January 11, 2010 by MassDevice staff

Echo Therapeutics Inc. (OTC:ECTE) reached a milestone with one of its two flagship products, the Prelude SkinPrep system, which is ready for clinical trials examining its use in dispensing lidocaine.

The Franklin, Mass.-based company, which is also developing a needle-free glucose monitoring system called the Symphony tCGM, said its development work on the Prelude system is complete and it's ready for a study in the "near term."

MicroCHIPS recognized by world economic forum

December 3, 2009 by MassDevice staff

What does MicroCHIPS Inc. have in common with Twitter?

Both were among a pool of 26 firms named 2010 Technology Pioneers by the World Economic Forum in Switzerland. The awards are handed out yearly to companies that are "involved in the development of a life-changing technology innovation and have the potential for long-term impact on business and society."

The 26 companies were winnowed from a pool of 300 applicants and judged by 58 "experts," according to the Swiss think tank, from the ranks of academia, media and industry.

Echo Therapeutics begins clinical study of transdermal glucose monitor

November 4, 2009 by MassDevice staff

Echo Therapeutics Inc. will complete a clinical study of its Symphony non-invasive, wireless transdermal continuous glucose monitoring system by the fourth quarter, in what would be a major step forward for a company that has burned through more than $60 million trying to bring its products to market.